degradation of cationic trypsinogen and thereby promoting trypsinogen autoactivation ( 1, 2 ) . An interesting exception is mutation p.A16V, which does not aff ect trypsinogen degradation. Instead, it increases CTRC-mediated processing of the trypsinogen activation peptide to a shorter form ( Figure 1 a ) , which, in turn, results in accelerated autoactivation (1) (2) (3) . Mutation p.A16V exhibits variable penetrance, indicating that disease onset requires additional risk factors ( 4, 5 ) . Here we report the discovery of the novel p.P17T mutation that mimics the eff ects of the p.A16V mutation and corroborates the pathological relevance of N-terminal trypsinogen processing by CTRC.
Th e index patient was a 30-year-old woman who was referred to the Hungarian Pancreatic Study Group for genetic testing and counseling. She was diagnosed with chronic pancreatitis at the age of 15 and suff ered at least 13 documented acute attacks since that time. Diagnostic signs of chronic pancreatitis included pancreas atrophy, parenchymal calcifi cations, Wirsung duct stones, and dilatation visualized by transabdominal US, abdominal CT, and therapeutic ERCP. Neither exocrine nor endocrine insuffi ciency was observed. She has smoked at least 7 pack years since age 23, whereas alcohol drinking history was unremarkable. For treatment of intractable pain and non-resolving common bile duct stenosis, she underwent multiple endoscopic pancreatic and biliary duct stent placement followed by combined surgical drainage and resection (Frey's procedure) of the pancreas and cholecystectomy at the age of 30. Aft er obtaining informed consent, we performed Sanger sequencing of all exons and fl anking intronic regions of the CTRC, CPA1 , PRSS1 , and SPINK1 genes and exons 4 and 11 of the CFTR gene. We found a novel heterozygous c.49C>A (p.P17T) variant in exon 2 of PRSS1 ( Figure 1 b ) To the Editor: Mutations in PRSS1 cause hereditary pancreatitis by reducing chymotrypsin C (CTRC)-dependent specifi c antibodies remained absent. In February2017, the patient presented with fatigue. Laboratory evaluation showed acute on chronic kidney disease, anion-gap metabolic acidosis, and supra-therapeutic tacrolimus levels. Imaging showed rapid progression of the disease with ten new pulmonary metastases, and enlargement of retroperitoneal mass. Liver enzymes, alkaline phosphatase, and liver function tests were not signifi cantly changed from baseline ( Table 1 ). Further evaluation did not demonstrate end-organ immune-related adverse events. Aft er involvement of primary oncology team, the patient declined further treatment. He passed away a week aft er discharged home with hospice.
Th e effi cacy and safety of immunotherapy for cancer in liver transplanted patients is not well studied. A review of published literature revealed two cases of liver transplant recipients treated with ipilimumab (CTLA-4 inhibitor) for melanoma ( 5 ) . At the time of ipilimumab treatment, the patients received low dose prednisone, plus tacrolimus, or everolimus. Th e patient receiving tacrolimus did not experience changes in liver enzymes; whereas the patient on everolimus had a transient rise in liver enzymes (biopsy was not performed). Of note, the tacrolimus-treated patient experienced rapid progression of his disease. A recent report recommended a combination of a glucocorticoid and sirolimus to prevent graft rejection in patients treated with PD-1 inhibitors ( 6 ). In our patient, lowdose tacrolimus therapy preserved the liver allograft . It may, however, have impaired the anti tumor effi cacy of pembrolizumab. Based on this report, we would like to highlight that immunotherapy with PD-1 inhibitors may be feasible in liver transplanted patients. Data from larger trials is needed to determine optimal immunemodulatory therapy to achieve optimal antitumor efficacy with transplant preservation.
trypsinogen. Mutation p.P17T showed similar biochemical characteristics as the known pathogenic mutation p.A16V and thus off ers independent validation for the notion that accelerated N-terminal processing of the trypsinogen activation peptide by CTRC is a relevant pathogenic mechanism in chronic pancreatitis.
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In conclusion, in an early-onset case of chronic pancreatitis we identifi ed the de novo PRSS1 mutation p.P17T in the activation peptide of human cationic SPINK1 p.N34S mutation was inherited from the unaff ected mother.
Functional analysis of the p.P17T mutant was performed using recombinant trypsinogen according to published protocols ( 2 ) . For comparison, wild-type and p.A16V mutant trypsinogen were also included. Rates of N-terminal processing by CTRC were increased 3.3-fold by mutation p.A16V and 1.7-fold by mutation p.P17T ( Figure 1 c ) , relative to wild type. As a consequence of stronger N-ter- To the Editor: Gamma-glutamyltransferase (GGT) is a membrane-bound glycoprotein that catalyzes the hydrolysis and transfer of a gamma-glutamyl residue from glutathione and other glutamyl compounds to amino acids or peptides ( 1 ). In human plasma, GGT has high intra-and inter-individual variability. Except for liver diseases, high-serum GGT activity could be detected in patients with some malignant carcinomas such as liver cancer, lung cancer, and colorectal cancer. Th e enzyme activity may increase aft er alcohol consumption ( 2 ). Here, and for the fi rst time, we report a case of apparently familial high-serum GGT activity with evidence in four generations. 
